Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Areas with lower population density have not seen the same slowdown as urban areas.
Developing treatments for fatty liver disease has proved challenging, and there are currently no approved medications.
Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.
The best-performing combo, firsocostat and cilofexor, showed benefits despite missing the main study endpoint.
Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.
People with advanced liver cirrhosis are at greater risk for severe COVID-19 illness and death.
The regulatory agency requested further data to show whether its benefits outweigh its risks.
Transplants due to hepatitis C have dropped dramatically, especially among people with liver cancer.
Those with NAFLD or NASH and cirrhosis should undergo regular screening.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
The tool relies on 14 clinical variables, such as liver enzymes, body mass index, triglycerides, height and sex.
Better treatments for hepatitis B and C and a lack of such advances for fatty liver or alcoholic liver disease are driving outcomes.
Liver fat may be a driver of increased cancer risk associated with obesity.
A recent study found that daily cannabis use was associated with a reduced risk of the liver condition in this population.
One of the major international conferences on all aspects of liver disease, opened Sunday in Washington, DC.
Recent tests found traces of glyphosate in the company’s products. The chemical has been linked to cancer and NAFLD.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.